Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAetna Medicare Part B preferred drug list Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy Y0001_NR_4168508_2025_C 4168505-01-01

    Medicare Part B preferred drug list (MAPD only)

    Customize your policy alerts

    Sign up for Aetna Policy Y0001_NR_4168508_2025_C 4168505-01-01 alerts

    Get alerted when Policy Y0001_NR_4168508_2025_C 4168505-01-01 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists medically administered Part B drugs with preferred and non-preferred products and notes when step therapy or prior authorization applies for Aetna Medicare Advantage plans that include prescription drug coverage (MAPD). Affects providers prescribing/administering Part B drugs for Aetna MAPD members.

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list (MAPD only)
    Policy CodePolicy Y0001_NR_4168508_2025_C 4168505-01-01
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionFollow linked step therapy and medical necessity criteria and submit required fax request forms when seeking prior authorization for non-preferred Part B drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipledrug categories listed
    notedstep therapy mentioned
    examplesprior auth not required examples
    HCPCS/JHCPCS/J-codes present

    Coverage Criteria and Category Rules

    Bone resorption inhibitors - step therapy

    Covered when ALL of the following are met for indicated conditions (summary from list):

    Tiered step therapy: Preferred product from both tiers required prior to receiving a non-preferred product for certain bone resorption inhibitor indications

    See linked criteria per product

    Specific indications: Indications subject to step therapy include osteoporosis, hypercalcemia of malignancy, prevention of skeletal events in multiple myeloma, prevention of skeletal events in prostate cancer or solid tumors with bone metastases, and treatment of osteopenia or osteoporosis in systemic mastocytosis

    Alpha-1 proteinase inhibitors - step therapy

    Covered when ALL of the following are met (alpha-1 antitrypsin deficiency example):

    Preferred agents first: Preferred alpha-1 proteinase inhibitors (Prolastin-C, Zemaira) should be used before non-preferred products

    HCPCS J0256/J0257 listed per product

    Neuromuscular and complement inhibitor coverage

    Covered when ALL of the following are met for neuromuscular and complement-related indications (examples):

    Botulinum toxins: Preferred botulinum toxin products (Botox J0585, Xeomin J0588) are listed; Botox and Xeomin are noted as prior authorization not required; other botulinum products are listed as non-preferred with links to criteria (e.g., Daxxify J0589, Dysport J0586, Myobloc J0587)

    Indications include cervical dystonia and blepharospasm; see per-drug links for criteria

    Complement inhibitors and immune therapies: Complement inhibitors (e.g., Soliris J1299, Ultomiris J1303, Uplizna J1823) are listed with HCPCS codes and links to medical necessity/step therapy criteria; step therapy may apply for indications such as hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria

    See product-specific links for exact requirements

    Supportive care agents coverage

    Covered when ALL of the following are met for supportive care agents:

    Colony stimulating factors / ESAs: Preferred short‑ and long‑acting colony stimulating factors and erythropoiesis stimulating agents are listed; some products are noted as prior authorization not required (examples: Zarxio Q5101; Procrit J0885) while others reference linked medical necessity or step therapy criteria

    Indications include anemia due to zidovudine in HIV and transfusion reduction for select surgeries; see links per product

    General coverage grouping (document references external criteria links)

    Covered when administrative and clinical criteria (linked) are met; some products are preferred and some are non-preferred with step therapy or prior auth requirements.

    Preferred product with no prior auth: Examples: Procrit (J0885/Q5127) and certain IV iron products (e.g., Ferrlecit J2916) are listed as prior authorization not required.

    See chunks 19 and 29 for examples.

    Product requiring medical necessity/step therapy criteria: Many products list 'Link to criteria' or 'See step therapy criteria' indicating prior authorization/step therapy requirements must be satisfied before coverage is approved.

    See multiple product entries where criteria links and fax forms are referenced.

    Category-level coverage and access rules (summary)

    Coverage, step therapy, and prior auth rules vary by drug and category; see linked criteria for full clinical requirements.

    Preferred vs Non-preferred product listings: Each drug entry is categorized as preferred or non‑preferred with an associated HCPCS/Q‑code and links to medical necessity criteria and fax forms where applicable.

    See individual product lines for prior auth or step therapy status.

    Ophthalmic VEGF inhibitors two-tier requirement: Preferred product from both tiers required prior to receiving a non‑preferred product for ophthalmic VEGF inhibitor indications.

    Applies to multiple ophthalmic VEGF inhibitors (examples: Avastin/Bevacizumab, Byooviz, Eylea, Beovu, Lucentis, Cimerli, etc.).

    Products with explicit prior auth not required: Some products explicitly state 'Prior authorization is not required' (examples include select chemotherapy and supportive agents such as Docetaxel J9171, Carboplatin J9045, Halaven J9179, Alimta J9305, Depo‑medrol J1010, Kenalog J3300/J3301).

    Other products reference linked criteria/fax forms and may require prior authorization.

    Step therapy and administrative coverage rules (general)

    Covered when ALL of the following are met

    Step therapy prerequisite: Preferred product from both tiers has been tried and documented prior to approval of a non‑preferred product

    Applies across ophthalmic VEGF inhibitors and many viscosupplements as indicated

    Product-specific administrative requirements: Submission of the product‑specific medical necessity criteria link and/or fax request form as indicated; use the HCPCS/J or Q code listed on requests and claims

    Some products explicitly state prior authorization is not required; others require fax forms and criteria links.

    Part D vs Part B routing

    Part D eligible products: Preferred products in certain immunologic classes may be covered under the Part D (pharmacy) benefit rather than Part B; when routed to Part D providers should follow 'See Part D benefit' instructions for medical necessity and request routing (examples include Hadlima, Rinvoq, Skyrizi SC, Stelara SC, Pyzchiva SC, Yesintek SC, Tremfya SC).

    See product entries for Part D routing and request instructions.

    General coverage condition

    Coverage available when product-specific medical necessity and step therapy criteria are met (see linked criteria); some agents are Part D not Part B.

    General requirement: Prior authorization and documentation per the linked medical necessity and step therapy criteria is required for listed Part B drugs; products routed to Part D are not initiated under Part B and must follow Part D processes.

    See product‑specific links and fax forms in the full policy for exact requirements.

    The policy groups drugs into preferred and non-preferred listings and applies step therapy where indicated. For classes with tiered preferences, a non-preferred product will generally only be covered after documented trial and failure of the preferred agent(s). Examples in the bone resorption inhibitor category show preferred products and linked medical necessity/step therapy criteria; where a product is non-preferred the listing references step therapy or prior authorization criteria that must be satisfied before coverage is approved.

    When an entry is labeled non-preferred or when an item is listed as for "All other indications," the policy indicates that those uses are subject to step therapy. Providers should expect that coverage for non-preferred agents or for indications listed as subject to step therapy requires adherence to the referenced step therapy/medical necessity links and any fax request forms before approval.

    For ophthalmic VEGF inhibitors, the policy requires trial of preferred products from both tiers before a non-preferred ophthalmic VEGF agent will be approved. The listing explicitly states a preferred product from both tiers is required prior to receiving a non-preferred product, and product lines include links to step therapy criteria and fax forms that must be followed for coverage.

    Some viscosupplements and selected single-injection agents are documented as "Prior authorization is not required" for specific products in the list (for example, Durolane and Synvisc/Synvisc-one entries note prior authorization not required). Where the entry states no prior authorization is required, those products may be administered without submitting a PA request according to the table entry.

    Certain agents are routed to the pharmacy benefit or otherwise excluded from Part B. Entries that indicate "See Part D benefit" or list HCPCS as "Not applicable" (for example, some SC formulations or indications) are not handled under this Part B policy and should be processed under the Part D benefit or per the instructions in the product-specific entry.

    When an entry explicitly states "Prior authorization is not required", that indicates the product is routingly covered without submission of a prior authorization for the specified HCPCS-coded product. Examples in this document include zoledronic acid and some viscosupplements where the table cell states prior authorization is not required; providers may bill those products without a PA per the listing.

    This partial document does not list detailed not medically necessary (NMN) rules. Explicit NMN determinations and clinical criteria are maintained in separate medical necessity documents referenced by the links in the listings. For specific NMN language, providers should consult the corresponding medical necessity criteria linked for each product.

    HCPCS / J-code / Code Listings

    Alpha-1 proteinase inhibitorsHCPCS
    J0256Alpha-1 proteinase inhibitor (listed for Prolastin-C/Zemaira/Aralast NP)
    J0257Glassia
    Bone resorption inhibitorsHCPCS
    J3489Zoledronic acid
    J2430Pamidronate
    J0897Prolia / Xgeva (denosumab / denosumab-related agents)
    J3111Evenity
    Q5136Jubbonti / Wyost / related HCPCS Q-code
    Botulinum toxinsHCPCS
    J0585Botox
    J0588Xeomin
    J0589Daxxify
    J0586Dysport
    J0587Myobloc
    Complement inhibitors / related immune therapiesHCPCS
    J1299Soliris (eculizumab) listed
    J1303Ultomiris
    J1823Uplizna
    J9332Vyvgart
    J9333Rystiggo
    J9334Vyvgart Hytrulo
    Colony stimulating factors / long-acting / erythropoiesis stimulating agentsHCPCS
    Q5101Zarxio
    J1447Granix
    J1442Neupogen
    J2506Neulasta
    J0885Procrit / Epogen (erythropoiesis stimulating agents)
    Q5127Rolvedon / related products
    Erythropoiesis stimulating agents (examples)HCPCS
    J0885Procrit / Epogen (erythropoiesis-stimulating agents)
    Reblozyl categoryHCPCS
    J0896Reblozyl
    Factor VIII (recombinant) examplesHCPCS
    J3385Category code used across multiple products (factor VIII, others)
    J7211Kovaltry
    J7209Nuwiq
    IV iron productsHCPCS
    J2916Ferrlecit / Sodium ferric gluconate
    J1750Infed
    J1756Venofer
    Q0139Feraheme
    J1439Injectafer
    J1437Monoferric
    IVIG, biologics, oncology biologics and biosimilars (examples)HCPCS
    J1561IVIG products (e.g., Gammaked, Gamunex-C)
    J1459Privigen
    J1552Alyglo
    J1559Hizentra (SCIG)
    J1558Xembify (SCIG)
    J2350Ocrevus
    J2329Briumvi
    J0202Lemtrada
    J9316Phesgo
    J9035Avastin
    1–10 of 14
    1/2
    Selected biologic HCPCS/Q-codes (from chunk 36)HCPCS
    Q5107Mvasi
    Q5118Zirabev
    Q5126Alymsys
    J9035Avastin
    Q5160Jobevne
    Q5129Vegzelma / Vegzelma (duplicate)
    Chemotherapy-related HCPCS codesHCPCS
    J9033Treanda
    J9036Belrapzo
    J9034Bendeka
    J9058Bendamustine
    J9056Vivimusta
    J9171Docetaxel
    J9045Carboplatin
    Herceptin, trastuzumab products and rituximab biosimilars codesHCPCS
    Q5117Kanjinti
    Q5112Ontruzant
    J9355Herceptin
    Q5146Hercessi
    Q5113Herzuma
    Q5114Ogivri
    Q5116Trazimera
    Q5119Ruxience
    Q5115Truxima
    Q5123Riabni
    1–10 of 12
    1/2
    Multiple myeloma and related agentsHCPCS
    J9179Halaven
    J9046Bortezomib/Velcade
    J9047Kyprolis
    J9145Darzalex
    J9144Darzalex Faspro
    Ophthalmic VEGF inhibitors and associated codesHCPCS
    C9257Bevacizumab (ophthalmic) misc billing code referenced
    J7999Bevacizumab (ophthalmic) misc billing code referenced
    Q5124Byooviz
    J0178Eylea
    J0177Eylea HD
    Q5147Pavblu
    J0179Beovu
    Q5128Cimerli
    J2778Lucentis
    Covered HCPCS codes (examples)HCPCS
    J0179Beovu (VEGF inhibitor, ophthalmic)
    Covered HCPCS codes (examples)HCPCS
    Q5128Cimerli (VEGF inhibitor, ophthalmic)
    Covered HCPCS codes (ophthalmic VEGF inhibitors)HCPCS
    J2778Lucentis (VEGF inhibitor, ophthalmic)
    J2779Susvimo (VEGF inhibitor, ophthalmic)
    J2777Vabysmo (VEGF inhibitor, ophthalmic)
    Q5153Opuviz (VEGF inhibitor, ophthalmic)
    Q5155Yesafili (VEGF inhibitor, ophthalmic)
    Viscosupplement HCPCS codesHCPCS
    J7318Durolane (viscosupplement)
    J7325Synvisc-one / Synvisc (viscosupplement)
    J7326Gel-one (viscosupplement)
    J7327Monovisc (viscosupplement)
    J7322Hymovis One / Hymovis (viscosupplement)
    J7323Euflexxa (viscosupplement)
    J7320GenVisc (viscosupplement)
    J7321Hyalgan / Supartz FX / Visco-3 (viscosupplements)
    J7324Orthovisc (viscosupplement)
    J7328Gelsyn-3 (viscosupplement)
    1–10 of 13
    1/2
    Immunologic / infliximab-related HCPCS codesHCPCS
    Q5121Avsola
    Q5103Inflectra
    Q5104Renflexis
    J1745Remicade / unbranded infliximab
    Q5098Imuldosa IV
    Q9999Otulfi IV (unclassified code listed)
    Q9998Selarsdi IV
    Q5099Steqeyma IV
    Q5138Wezlana IV
    Additional HCPCS codes for biologicsHCPCS
    J2267Omvoh
    J0717Cimzia
    J2323Tysabri
    J3590Starjemza (infusion code listed)
    Juvenile/other grouping codesHCPCS
    J1602Placeholder code used repeatedly for juvenile indications / preferred drug grouping
    J3262Actemra (tocilizumab) for J1602 grouping
    Covered HCPCS/J/Q codes mentionedHCPCS
    J1745Remicade / Unbranded infliximab (listed as HCPCS/J code)
    J0717Cimzia
    J1602Simponi Aria (and used as a category label in list)
    Q5104Renflexis
    Q5121Avsola
    Q5103Inflectra
    J0129Orencia
    J3262Actemra
    J9312Rituxan
    Q5123Riabni
    1–10 of 19
    1/2
    Part D coverage routing — preferred products may be Part D
    ScopePreferred products within certain immunologic classes may be covered under the Medicare Part D (pharmacy) benefit instead of Part B (medical)
    ExamplesImmunologics for ulcerative colitis (e.g., Hadlima, Rinvoq, Skyrizi SC, Stelara SC, Pyzchiva SC, Yesintek SC, Tremfya SC) are listed with 'See Part D benefit' instructions
    Action for providersFollow the 'See Part D benefit' routing and submit requests via the Part D process (request/routing instructions shown next to each product)
    Where to confirmRefer to the product-specific lines in the policy for 'See Part D benefit' and the linked medical necessity/step therapy instructions

    Prior Authorization, Step Therapy, and Submission Requirements

    Prior Authorization

    Prior authorization varies by drug — some products show PA not required

    Many listed drugs show that prior authorization is not required for specific products (example: Botox J0585; Zarxio Q5101; Neulasta J2506 entries indicate PA status). Providers should verify per-drug PA guidance and follow any linked instructions where present.

    • Example: Zarxio (Q5101) — “Prior authorization is not required.” [[source]]
    • Example: Neulasta / Neulasta Onpro (J2506) — Neulasta Onpro entry shows “not required.” [[source]]
    • Botulinum toxin examples (Botox J0585 referenced in broader summary).
    Prior Authorization

    Some products explicitly list prior authorization as not required

    Several individual product entries explicitly state “Prior authorization is not required” (for example: Procrit J0885, Ferrlecit J2916, Eligard J9217, Firmagon J9155). Providers should confirm PA status for the specific HCPCS/J code they will bill.

    • Procrit (J0885) — listed with “Prior authorization is not required.”
    • Ferrlecit / sodium ferric gluconate (J2916) — listed as “Prior authorization is not required.”
    • Eligard (J9217) — entry shows “Prior authorization is not required.”
    • Firmagon (J9155) — entry shows “Prior authorization is not required.”
    Prior Authorization

    PA requirements differ — some entries point to linked criteria/fax forms

    Many entries alternate between explicitly stating PA is not required and referencing external medical necessity or step therapy criteria with a fax request form. Providers must follow the per-product guidance: if a “Link to criteria” or “Link to fax form” is present, submit per that guidance.

    • When a product line shows “Link to criteria” or “Link to fax form,” use those linked medical necessity/step therapy documents and fax request forms.
    • When a product line shows “Prior authorization is not required,” no PA submission is listed for that product in this document.
    Prior Authorization

    Prior authorization for viscosupplements/selected HCPCS products — varies by product

    Viscosupplements and selected HCPCS-coded agents have mixed PA expectations: some (e.g., Durolane, Synvisc-one) show prior authorization is not required, while other viscosupplements reference medical necessity or step therapy links and may require PA submissions.

    • Durolane (J7318) — entry shows fax request form = “Prior authorization is not required.”
    • Synvisc-one / Synvisc (J7325) — entries indicate “Prior authorization is not required.”
    • Other viscosupplement entries include links to medical necessity or step therapy criteria — follow linked forms if present.
    Prior Authorization

    Prior authorization requirement — reference product-specific criteria and fax forms

    Many products listed require prior authorization per Aetna medical necessity and/or step therapy criteria; PA requests should reference the specific HCPCS/J or Q code and use the product-specific fax request form when indicated.

    • Include the product HCPCS/J or Q code on PA requests as shown in the product line (examples shown across chunks 72, 78, 81).
    • If a product line includes “Link to fax form” or “Link to criteria,” submit documentation per those linked forms.
    Step Therapy

    Step therapy — try preferred product(s) first; exception process available

    Step therapy requires that preferred products be tried first; an exception process exists for clinical reasons. Providers must follow the step therapy criteria in the linked documents if the product or indication is marked subject to step therapy.

    • The policy defines step therapy as requiring preferred drugs be tried before non-preferred alternatives (see policy overview).
    • An exception process is available for specific clinical cases that may call for a non-preferred product.
    Step Therapy

    Step therapy applies to many listed indications — follow per-drug criteria

    Step therapy is applied across many indications and product categories; multiple entries are labeled “Indications subject to step therapy” or reference ‘Step therapy criteria’ links that must be followed for coverage.

    • Examples include erythropoiesis stimulating agents, enzyme replacement therapy, and IV iron products — see each product’s ‘Link to criteria’ for required trials.
    • Providers must document trials/failures as required by the linked step therapy criteria.
    Step Therapy

    Step therapy applicable for many indications — linked criteria define required trials

    Multiple categories and specific indications are subject to step therapy; several product lines explicitly point to “Step therapy criteria” links that define required prior trials and sequencing.

    • Rituximab entries note step therapy applies to all requests except rheumatoid arthritis — follow the linked step therapy criteria.
    • Ophthalmic VEGF inhibitors and many oncology and immunologic agents are marked subject to step therapy; use linked documents for specifics.
    Step Therapy

    Step therapy required for many VEGF inhibitors and viscosupplements — preferred-tier trials required

    For ophthalmic VEGF inhibitors and many viscosupplements, step therapy requires trial of a preferred product from both tiers before coverage of a non-preferred product; follow the product-specific step therapy links and fax forms.

    • Ophthalmic VEGF inhibitor examples: Byooviz (Q5124), Eylea (J0178), Beovu (J0179), Lucentis (J2778) — each notes preferred-tier requirements and links to step therapy criteria and fax forms.
    • Viscosupplement examples: Durolane (J7318), Synvisc-one (J7325) — entries show mixture of ‘not required’ and linked criteria; follow the line-item guidance.
    Step Therapy

    Follow linked step therapy criteria documents for specifics

    When an item is marked subject to step therapy, providers must follow the linked step therapy criteria documents for the specific required prior trials, acceptable failures, and any documentation requirements.

    • Linked documents contain the exact trial durations, acceptable failure definitions, and documentation templates.
    • If the product is routed to Part D per the entry, follow the Part D routing instructions in the linked criteria.
    Documentation Required

    Use linked medical necessity criteria and fax request forms where indicated

    Many product entries include a “Link to criteria” and a “Link to fax form”; providers must use those medical necessity criteria and fax request forms when submitting prior authorization or step therapy exception requests.

    • If a product line shows a fax request form link, use that form for PA submissions as indicated.
    • When a ‘Link to criteria’ is present, supply the clinical documentation described in that external criteria document.
    Prior Authorization

    Procrit (J0885) — prior authorization not required (example)

    Procrit (J0885) is listed in the erythropoiesis stimulating agents grouping and is noted specifically as “Prior authorization is not required.” Providers administering Procrit do not need to submit a PA per this listing.

    • Procrit entry: “Prior authorization is not required.”
    • No fax request form is indicated for Procrit in this entry.
    Documentation Required

    Many entries include links to medical necessity criteria and fax forms — use them for submissions

    Many product entries reference both a ‘Link to medical necessity criteria’ and a ‘Link to fax form,’ indicating that providers must submit the specified fax request and meet the linked clinical criteria for approval.

    • Examples include bevacizumab/Avastin and its biosimilars (links to criteria and fax forms) and multiple oncology biologics with fax forms referenced.
    • Where a fax form link is shown, use that form to submit prior authorization requests.
    Documentation Required

    Fax request forms and criteria links present for multiple products (examples: Beovu, Cimerli, Lucentis)

    Specific products list a fax request form or medical necessity link on their line (examples: Beovu, Cimerli, Lucentis), and providers should use those fax forms and criteria links when submitting authorization requests.

    • Beovu (J0179) — “Fax request form = Link to fax form.”
    • Cimerli (Q5128) — entry includes link to fax form and step therapy criteria.
    • Lucentis (J2778) — entry shows link to fax form and link to criteria.
    Documentation Required

    Submission and documentation — use referenced fax forms and criteria links

    Providers must submit PA or step therapy exception requests using the referenced fax request forms and include documentation that meets the linked medical necessity or step therapy criteria for the product and indication.

    • Include the HCPCS/J/Q code for the specific product on the request as shown in the product line.
    • Attach clinical documentation consistent with the linked medical necessity or step therapy criteria.
    Denial Risk

    Denial risk — step therapy not followed can trigger denial

    Failure to follow step therapy requirements may result in denial of coverage; the policy states coverage may be denied if step therapy is not followed where it applies.

    • Step therapy requires trying preferred products first; lacking documented trials/failures per criteria may lead to noncoverage.
    • Use the exception process when clinically appropriate and document reasons per the linked criteria.
    Denial Risk

    Step therapy may trigger denial for select IV iron products — follow linked criteria

    Select IV iron products (Feraheme Q0139/Q0138, Injectafer J1439, Monoferric J1437) reference step therapy criteria; providers should document required prior trials or indications per those links to avoid possible denial.

    • Feraheme (Q0139/Q0138) — “See step therapy criteria” and link to fax form.
    • Injectafer (J1439), Monoferric (J1437) — entries reference step therapy criteria and fax forms.
    Step Therapy

    Preferred-tier requirement for ophthalmic VEGF inhibitors — trial of preferred products from both tiers required

    Use of non-preferred ophthalmic VEGF inhibitors requires documented trial and failure of preferred products from both tiers prior to coverage of a non-preferred product; follow the product-specific step therapy links and include required documentation on the fax form.

    • Examples: Beovu, Eylea, Byooviz, Lucentis entries all note the two-tier preferred-product requirement and link to step therapy criteria/fax forms.
    • Document trials of preferred products from both tiers as required by the linked criteria.
    Denial Risk

    Step therapy general requirement — missing required trials may lead to denial

    Prescribers may be denied coverage if step therapy prerequisites are not met; the policy emphasizes that a preferred product from both tiers is required prior to receiving a non-preferred product for listed indications.

    • This general step therapy rule applies across multiple categories (ophthalmic VEGF inhibitors, viscosupplements, other listed drugs).
    • Follow linked step therapy documents to ensure required prior trials are met.
    Billing Rule

    HCPCS/J/Q-linked prior auth risk — include the listed code and follow PA/step therapy rules

    Coverage for many ophthalmic VEGF inhibitors is tied to HCPCS/J/Q codes and subject to step therapy and prior authorization risks associated with those codes; include the specified code on authorization and claims submissions.

    • Examples: Beovu (J0179), Cimerli (Q5128), Lucentis (J2778), Susvimo (J2779), Vabysmo (J2777) — each entry includes HCPCS/J/Q codes and links to criteria/fax forms.
    • Use the HCPCS/J/Q code listed in the product line on PA requests and claims.
    Denial Risk

    Denial risk from unmet criteria — follow linked medical necessity and step therapy documents

    Failure to follow the referenced step therapy or medical necessity criteria (which are hosted in separate linked documents) can change coverage/access and may trigger noncoverage or denial; providers must adhere to the linked criteria and submission requirements.

    • The policy repeatedly references external criteria and fax forms — those documents contain the clinical conditions and documentation needed for approval.
    • Providers should review the linked criteria before submitting a PA or step therapy exception request.
    Note

    Key Terms and Routing

    Step therapy — definition
    DefinitionStep therapy is a coverage requirement that requires trying preferred drug(s) first before covering a non-preferred alternative
    PurposeTo ensure preferred (typically lower-cost or clinically preferred) products are used prior to authorizing non-preferred drugs
    ExceptionAn exception process exists for clinical reasons when a preferred product is not appropriate
    Part D routing — explanation
    Policy noteSome preferred products within listed immunologic classes may be covered under the Part D (pharmacy) benefit rather than Part B (medical)
    Product-level routingIndividual products (for example Hadlima, Rinvoq, Skyrizi SC, Stelara SC, Pyzchiva SC, Yesintek SC, Tremfya SC) are annotated with 'See Part D benefit' or 'Request through' to indicate Part D handling
    Provider actionWhen a product line indicates 'See Part D benefit', route prior authorization/requests per Part D instructions rather than Part B medical benefit forms
    Part D / Part B distinction — benefit routing
    Benefit distinctionSome agents are administered under the medical benefit (Part B) while others are handled under the pharmacy benefit (Part D); the policy marks products that should be routed to Part D
    ExamplesThe policy lists specific immunologics and, for some indications (e.g., ulcerative colitis), annotates products with 'See Part D benefit' or 'Request through' to indicate Part D coverage
    How to verifyConfirm routing by checking the product line in the policy for the 'See Part D benefit' note and follow the linked criteria or request instructions

    Initial Therapy / First-Line Requirements

    Initial therapy requirements (class-level)

    Preferred products required prior to non-preferred for certain classes

    Tier requirement: Preferred product from both tiers required prior to receiving a non‑preferred product for bone resorption inhibitors where noted

    See per‑drug links for exact prior authorization or step therapy criteria

    Initial therapy step requirement

    Step therapy prerequisite

    Tiered preferred product requirement: Preferred product from both tiers must be used before a non‑preferred product is approved for classes where two‑tier sequencing is specified (example: ophthalmic VEGF inhibitors).

    Documentation of trials is required per linked step therapy criteria.

    Initial therapy rules (referenced)

    Initial coverage requires meeting step therapy and/or medical necessity criteria where indicated.

    Initial therapy general: Provider must follow the linked step therapy and medical necessity criteria for product‑specific initial therapy requirements; some agents require Part D routing and are not initiated under Part B.

    See Aetna step therapy and product‑specific criteria documents linked in the policy.

    Step Therapy Tables and Requirements

    RequirementDetails
    Must try preferred drug(s) first
    Step therapy requires trial of listed preferred products before approval of a non-preferred product; an exception process exists for specific clinical reasons
    ScopePolicy note
    Multiple categories and products (e.g., erythropoiesis stimulating agents, IVIG) are marked 'Indications subject to step therapy'
    Product entries reference 'Link to criteria' or 'Step therapy criteria' for specific prior trials and sequencing; see linked criteria for details
    Drug / categoryStep therapy rule
    Rituximab (including originator and biosimilars)
    Step therapy applies to all requests except rheumatoid arthritis; preferred biosimilars Ruxience and Truxima are listed as preferred (step therapy links and fax forms provided for other products)
    Class / examplesStep therapy requirement
    Ophthalmic VEGF inhibitors (examples: Bevacizumab/Avastin, Byooviz, Eylea, Pavblu, Beovu, Cimerli, Lucentis)
    Preferred products from both tiers must be tried and documented prior to approval of a non-preferred ophthalmic VEGF inhibitor; product-specific step therapy criteria and fax forms are referenced
    ApplicabilityRequirement
    Ophthalmic VEGF inhibitors and selected viscosupplements (general rule referenced across entries)
    A preferred product from both tiers is required prior to receiving a non-preferred product; documentation and product-specific criteria links are provided for required trials
    General ruleAction for providers
    Where a product or indication is labeled 'subject to step therapy', the step therapy sequence must be followed
    Follow the product-specific step therapy criteria linked in the policy (use the linked medical necessity criteria and fax request form where indicated) to document required trials/ failures

    Site of Care / Administration Notes

    Billing Rule

    Infusion-center or office administration — check local billing/site rules

    Site-of-care specifics are not provided in this section; many agents listed are administered in infusion centers or office settings when billed under Part B.

    • Confirm site-of-care billing rules with the applicable plan or facility as they are not detailed here.

    Biosimilar Groupings and Links

    Billing Rule

    Avastin (bevacizumab) biosimilars — reference criteria/fax form

    Avastin and its biosimilars (e.g., Mvasi Q5107) are listed with links to criteria and fax forms; providers should reference those links when requesting coverage.

    • Mvasi (Q5107) and Zirabev (Q5118) entries include links to medical necessity criteria and fax request forms.
    Billing Rule

    Avastin grouping — HCPCS Q5118 and criteria links

    Avastin is listed with HCPCS Q5118 and a link to criteria; biosimilars and the originator are grouped under the Avastin category — use the product line links for PA/documentation requirements.

    • Avastin (J9035) and biosimilars Mvasi (Q5107), Zirabev (Q5118) have product-specific links to criteria and fax forms.
    Billing Rule

    Bevacizumab (Avastin) — preferred with HCPCS Q5107; see criteria/fax form

    Bevacizumab (reference biologic Avastin) and its biosimilars are listed as preferred with HCPCS Q5107 and include links to criteria and fax forms for PA/submission.

    • Use the listed HCPCS/Q codes and the linked fax form when a PA or documentation submission is required.
    Billing Rule

    Bevacizumab biosimilar listing (Q5118) — follow linked forms/criteria

    Bevacizumab entries include HCPCS Q5118 and reference to criteria and fax forms — follow those links for PA and documentation guidance.

    • Providers should use the product-specific links for prior authorization submission when indicated.
    Billing Rule

    Trastuzumab (Herceptin) and biosimilars — reference HCPCS/Q-codes and criteria

    Trastuzumab (Herceptin) and multiple biosimilars are listed with HCPCS/Q-codes and links to medical necessity criteria and fax forms; include those references when submitting requests.

    • Kanjinti (Q5117), Ontruzant (Q5112), Herceptin (J9355) entries include links to criteria and fax forms.
    Billing Rule

    Remicade group — Inflectra (Q5103) listed with criteria links

    Inflectra (Q5103) is listed under Remicade/infliximab groupings with links to medical necessity criteria and fax forms; follow the listed criteria for PA and step therapy where applicable.

    • Inflectra, Renflexis, Avsola and Remicade entries include links to criteria and fax forms for submissions.
    Billing Rule

    Avsola (Q5121) — infliximab listing with criteria/fax form

    Avsola (Q5121) is listed with links to medical necessity criteria and a fax request form in the infliximab section; use those links for authorization and documentation.

    • Avsola appears in preferred/unpreferred groupings; check the product line for step therapy and PA instructions.
    Billing Rule

    Remicade/infliximab — Q5121 appears in non-preferred/biosimilar groupings; follow criteria

    Remicade/infliximab entries include HCPCS Q5121 among non-preferred or biosimilar groupings and reference linked medical necessity criteria — submit PA per those links.

    • Providers should reference the HCPCS/J/Q code listed and the linked criteria/fax form when requesting coverage.
    Billing Rule

    Remicade/infliximab — Q5103 listed; use linked criteria/fax form

    Remicade/infliximab is also listed with HCPCS Q5103 in non-preferred/biosimilar groupings; linked medical necessity criteria and fax forms apply for PA and step therapy.

    • Inflectra (Q5103) and related entries include links to criteria and fax request forms — use them for submissions and documentation.
    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list (MAPD only)
    Policy CodePolicy Y0001_NR_4168508_2025_C 4168505-01-01
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionFollow linked step therapy and medical necessity criteria and submit required fax request forms when seeking prior authorization for non-preferred Part B drugs.
    SourceLink
    On This Page
    Coverage Criteria and Category RulesHCPCS / J-code / Code ListingsPrior Authorization, Step Therapy, and Submission RequirementsKey Terms and RoutingInitial Therapy / First-Line RequirementsStep Therapy Tables and RequirementsSite of Care / Administration NotesBiosimilar Groupings and Links
    Indications subject to step therapy: Many indications (for example certain oncology, immunologic and hematologic conditions) are marked as subject to step therapy with product‑specific links to step therapy criteria; rituximab entries note step therapy applies to all requests except rheumatoid arthritis.

    See the per‑drug entries and links for exact sequencing and exceptions.